Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...3940414243444546474849...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, RSL3 / Stanford University
    Journal:  Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. (Pubmed Central) -  Mar 25, 2022   
    Cetuximab promoted RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 in KRAS mutant CRC cells, and this was further demonstrated in a xenograft nude mouse model. Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. (Pubmed Central) -  Mar 24, 2022   
    In turn, KRAS-reprogrammed macrophages were shown to not only promote tumor progression but also induce the resistance of tumor cells to cetuximab therapy...Mutant KRAS increased the production of reactive oxygen species, an inhibitor of prolyl hydroxylase activity which decreases HIF-1α hydroxylation, leading to enhanced HIF-1α stabilization. This cell-extrinsic mechanism awards KRAS a critical role in engineering a permissive microenvironment to promote tumor malignancy, and may present new insights on potential therapeutic defense strategies against mutant KRAS tumors.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, IO biomarker:  Interleukin-33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer. (Pubmed Central) -  Mar 23, 2022   
    Effective cetuximab treatment induced a change of IL-33 and OPN at the early stage and triggered the NK cells antitumor activity. Consequently, significantly increased IL-33 level and decreased OPN level in the peripheral blood at the early treatment are proposed as potential predictors of cetuximab treatment efficacy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Cancer of the Larynx and Hypopharynx. (Pubmed Central) -  Mar 19, 2022   
    In addition, the immune system is vital in the prevention of recurrence, and various immunomodulators against programmed cell death receptor 1 are being investigated. Multidisciplinary management of the patient with laryngeal and hypopharyngeal is key, as many vital functions are affected by this devastating disease.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lumigan (bimatoprost) / Senju, AbbVie
    Review, Journal:  Eyelash Trichomegaly: A Systematic Review of Acquired and Congenital Etiologies of Lengthened Lashes. (Pubmed Central) -  Mar 17, 2022   
    Congenital disorders associated with lengthened eyelashes included Cantú syndrome, CHOPS syndrome, Coffin-Siris syndrome, congenital heart disease, Cornelia de Lange syndrome, Costello syndrome, familial trichomegaly, Floating Harbor syndrome, Hermansky-Pudlak syndrome, Kabuki-Makeup syndrome, KBG syndrome, Oliver-McFarlane syndrome, Rubinstein-Taybi syndrome, and Smith-Magenis syndrome. While the most common cause of eyelash trichomegaly is topical bimatoprost use, better understanding of pathways implicated in eyelash trichomegaly may lead to the discovery of additional medications to stimulate eyelash growth and create avenues for future therapeutic interventions.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal, Heterogeneity:  Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging. (Pubmed Central) -  Mar 17, 2022   
    Biopsies can be highly invasive procedures and provide a limited sample of molecular expression within a tumor. Our nanoparticle-based Raman imaging approach offers the potential to provide non-invasive and more comprehensive molecular imaging and an alternative to the current clinical gold standard of immunohistochemistry.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Comparative study on application ofLu-labeled rituximab, tetulomab, cetuximab and huA33 monoclonal antibodies to targeted radionuclide therapy. (Pubmed Central) -  Mar 15, 2022   
    The dependencies on absorbed dose for the alveolar, bronchioles, bone surface, heart wall, kidneys, liver, lung, lymphatic nodes, and spleen, are presented. For tumours, the absorbed dose for each drug is calculated separately for a sphere of unit volume by using the information on the injected dose.Conclusion, The ratios of the dose coefficient for the tumour to each organ, indicate that lutetium-177 can be recommended for targeted radionuclide therapy since the dose per tumour is much greater than the dose per organ.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal:  Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. (Pubmed Central) -  Mar 12, 2022   
    A combination of Caveolin-1 and Sox-2 protein levels was sufficient to maintain high predictive accuracy, which we validated in HNSCC patient tumor samples with known clinical response to cetuximab. These results support further investigation into the combined use of Caveolin-1 and Sox-2 as predictive biomarkers for cetuximab response in the clinic.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Melanoma and eruptive nevi during cetuximab treatment: EGFR inhibitors and a common concern. (Pubmed Central) -  Mar 11, 2022   
    A 59-year-old patient was referred to the Melanoma Unit for a dermatologic consultation due to the eruptive onset of multiple hyperpigmented nevi one-month after the beginning of their medical therapy with cetuximab for metastatic colorectal cancer. No other side-effects were reported, with the exception of a mild cutaneous xerosis.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  Severe anaphylaxis caused by intravenous anti-cancer drugs. (Pubmed Central) -  Mar 11, 2022   
    No other side-effects were reported, with the exception of a mild cutaneous xerosis. We elucidated the high-risk settings of chemotherapy-induced severe anaphylaxis.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. (Pubmed Central) -  Mar 11, 2022   
    In this work, all these active targeted nanomedicines are discussed, analyzing their advantages and disadvantages over conventional chemotherapy as well as the challenges involved in their lab to clinical translation. In addition, examples of formulations developed and evaluated at the preclinical level are also discussed.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (clinicaltrials.gov) -  Mar 11, 2022   
    P2,  N=78, Recruiting, 
    In addition, examples of formulations developed and evaluated at the preclinical level are also discussed. Trial completion date: Dec 2021 --> Aug 2026 | Trial primary completion date: Jul 2021 --> Jul 2026
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  TPExtreme: Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) -  Mar 11, 2022   
    P2,  N=541, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Aug 2026 | Trial primary completion date: Jul 2021 --> Jul 2026 N=416 --> 541 | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Jan 2019 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion:  SAKK 16/08: Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Mar 10, 2022   
    P2,  N=69, Completed, 
    N=416 --> 541 | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Jan 2019 --> Dec 2022 Active, not recruiting --> Completed
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, HEOR:  Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. (Pubmed Central) -  Mar 9, 2022   
    In NSCLC SCC, a combination index of EGFR FISH plus EGFR IHC results was associated with improved OS when cetuximab was added to CT, representing a potential predictive molecular paradigm for patients suitable for EGFR-antibody therapy. FOLFIRI plus cetuximab is cost-effective compared with FOLFIRI plus bevacizumab or FOLFIRI alone in RAS wild-type left-sided mCRC and patients who undergo resection.